In humans, it has been demonstrated that the serum circulating levels of TRAIL are significantly reduced in patients with T1DM, with the lowest levels observed in those presenting with ketoacidosis at onset and those with the highest insulin requirements, reflecting an advanced severity of the underlying disease [23]. This evidence concerns the gene TNFSF10 and type 1 diabetes mellitus.